Lilly may extend grant disclosure policy globally

Share this article:
Eli Lilly said it is studying the feasibility of extending its grants disclosure policy globally and could do so by next year.

Publishing the data on worldwide education grants and charitable contributions would complement the Indianapolis drug firm's decision last May to publicize grants given to US organizations. Lilly posts the information on its educational grants portal on a quarterly basis.

Lilly CEO Sidney Taurel said the firm is “working hard to evaluate the legal, regulatory and other considerations” related to disclosing the information worldwide, targeting 2008 as a possible timeframe.

He made the statement in a letter to the group Essential Action, which is leading a broad coalition of public health and consumer organizations leaning on Big Pharma to disclose all of its charitable and educational grants and gifts. Arguing that such funding influences physician prescribing, the coalition said disclosure “doesn't cure this problem, but it is a start.”

So far, the only company set to follow Lilly onto the grant disclosure bandwagon is Pfizer. In April its Medical Education Policy Committee recommended the adoption of a policy on disclosure of educational grants. The company will begin reporting grants given to US organizations in 2008.

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.